company-header-background

Formulation
Solutions

Formulation Solutions leverages Precision NanoSystems’ research facilities, technical team and NanoAssemblr® Platform to design flexible, custom nanomedicine formulation and nanoparticle manufacturing process development solutions.
Overview

Formulation Solutions projects span the entire nanoparticle formulation development continuum—from proof-of-concept nanoparticle formulations in early discovery to advancing lead candidate development in scale-up, to optimization and technology transfer of nanoparticle manufacturing processes to CMO/manufacturing sites for cGMP production.

The Precision NanoSystems team uses proprietary NanoAssemblr® microfluidic technology to develop optimized process parameters for the manufacture of lipid or polymer-based nanomedicines that meet target specifications.

 

Formulation Solution Experts


Examples of Formulation Solutions Projects and Deliverables

• Nanoparticle formulation(s) suitable for proof-of-concept and pre-clinical testing

• Manufacturing support for NanoAssemblr® Benchtop and Blaze users

• Tech transfer plan and manufacturing support to CMO/manufacturing site (for NanoAssemblr® GMP System)

• Standard Operating Protocols for nanoparticle manufacture using the NanoAssemblr® platform and products

• Standard Operating Protocols for downstream (ultrafiltration and diafiltration) processing of nanoparticles

• Analysis of nanoparticle physicochemical and biological properties

The Formulation Solutions team collaborates with customers to develop a well-defined project plan, with identified project deliverables, timeline, and budget.


Talk to a Formulations Expert

Formulation Solutions projects span the entire nanoparticle formulation development continuum—from early discovery proof-of-concept nanoparticle formulations to CMO/manufacturing sites for cGMP production.

Talk to a Formulations Expert







Brochure
Formulation Solutions BrochureFor more information, please follow the link below for our Formulation Solutions brochure.

Download

Resource Center

Publication - Abstract

July 01, 2020

Journal of Controlled Release

Delivery of Self-amplifying mRNA Vaccines by Cationic Lipid Nanoparticles: The Impact of Cationic Lipid Selection

G. Lou, G. Anderluzzi, S.T. Schmidt, S. Woods, S. Gallorini, M. Brazzoli, F. Giusti, I. Ferlenghi, R. Johnson, C.W. Rob...

Read More 阅读更多

Publication - Abstract

May 08, 2020

Vaccines

Investigating the Impact of Delivery System Design on the Efficacy of Self-Amplifying RNA Vaccines

G. Anderluzzi, G. Lou, S. Gallorini, M. Brazzoli, R. Johnson, D.T. O'Hagan, B.C. Baudner and Y. Perrie

Read More 阅读更多

Publication - Abstract

April 02, 2020

Journal of Controlled Release

Design of a Novel Vaccine Nanotechnology-based Delivery System Comprising CpGODN-protein Conjugate Anchored to Liposomes

D. Chatzikleanthous, S.T. Schmidt, G. Buffi, I. Paciello, R. Cunliffe, F. Carboni, M.R. Romano, D.T. O'Hagan, U. D'Oro, ...

Read More 阅读更多

Publication - Abstract

December 31, 2019

Vaccines

Investigating Prime-Pull Vaccination through a Combination of Parenteral Vaccination and Intranasal Boosting

C.B. Roces, M.T. Hussain, S.T. Schmidt, D. Christensen and Y. Perrie

Read More 阅读更多

Publication - Abstract

May 31, 2019

Vaccine

mRNA Vaccines Against H10N8 and H7N9 Influenza Viruses of Pandemic Potential Are Immunogenic and Well Tolerated in Healthy Adults ...

R.A. Feldman, R. Fuhr, I. Smolenov, A. Ribeiro, L. Panther, M. Watson, J.J. Senn, M. Smith, Ö. Almarsson, H.S. Pujar, M....

Read More 阅读更多

Publication - Summary

May 18, 2019

Annals of Hematology

Lipid Nanoparticle-mediated siRNA Delivery for Safe Targeting of Human CML In Vivo

N. Jyotsana, A. Sharma, A. Chaturvedi, M. Heuser et al.

Read More 阅读更多
Resource Center 资源中心
MENU
菜单
X
X